Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Dateline City:
KENILWORTH, N.J.
Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced topline results from the KEYNOTE-010 study of KEYTRUDA®
(pembrolizumab) in advanced non-small-cell lung cancer (NSCLC)
demonstrating that the trial met its primary objective.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Lung Cancer | Merck | Non-Small Cell Lung Cancer | Study